{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:07:56Z","timestamp":1779700076167,"version":"3.53.1"},"reference-count":23,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Psoriasis patients aged over 65 years, especially those with chronic comorbidities, constitute an increasingly important patient population. In this group, the selection of therapy, along with its efficacy and safety, is of relevance. Materials and Methods: A single-center retrospective analysis of clinical records of patients aged \u2265 65 years with moderate to severe plaque psoriasis, treated with biologic therapies. The study covered the period 2019\u20132025. Results: A total of 38 patients were included. Biologic switching occurred in 15 patients (39.5%). The primary reason for switching was loss of efficacy (86.7%), while adverse events accounted for 13.3% of cases. The mean duration from initiation of adalimumab (the mandatory first-line biologic therapy) to switching was 325 \u00b1 191 days. Baseline PASI did not differ significantly between groups (p = 0.139). Psoriatic arthritis was significantly less frequent among patients who switched therapy (13.3% vs. 56.5%, p = 0.008). No significant associations were observed between switching and comorbidities or overall comorbidity burden (p &gt; 0.05). Clinically relevant adverse events included infections, cardiovascular events, malignancies, and autoimmune laboratory abnormalities. Conclusions: Biologic therapy in elderly psoriasis patients appears to be generally well tolerated, based on descriptive real-world data. Treatment switching was primarily driven by loss of efficacy rather than comorbidities.<\/jats:p>","DOI":"10.3390\/medicina62050911","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:16Z","timestamp":1778274436000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Biologic Therapy in Elderly Patients with Moderate-to-Severe Psoriasis: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-8003","authenticated-orcid":false,"given":"Vanda","family":"Bondare-Ansberga","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Riga Stradins University, Baznicas Street 18, LV-1010 Riga, Latvia"},{"name":"Riga 1st Hospital, Bruninieku Street 5, LV-1001 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grigorjeva","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Riga Stradins University, Baznicas Street 18, LV-1010 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref_1","unstructured":"Michalek, I.M., Loring, B., and John, S.M. (2016). Global Report on Psoriasis, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jvc2.285","article-title":"Prevalence of multiple long-term conditions with psoriasis in England: A cohort study using the Clinical Practice Research Datalink","volume":"3","author":"Payne","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1203475419897578","article-title":"Biologic Treatment in Elderly Patients with Psoriasis: A Systematic Review","volume":"24","author":"Sandhu","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.15139","article-title":"Elderly psoriatic patients under biological therapies: An Italian experience","volume":"33","author":"Ricceri","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","unstructured":"WHO (2026, March 15). Aging and Health. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health."},{"key":"ref_7","unstructured":"United Nations (2023). World Population Ageing 2023, United Nations."},{"key":"ref_8","unstructured":"ICH (1994). E7: Studies in Support of Special Populations: Geriatrics-Step 5, ICH\u2013The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Reference Number: EMA\/CHMP\/604661\/2009."},{"key":"ref_9","unstructured":"EMA (2026, March 15). Humira, INN-Adalimumab, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf."},{"key":"ref_10","unstructured":"EMA (2026, March 15). Stelara, INN-Ustekinumab, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf."},{"key":"ref_11","unstructured":"EMA (2026, March 15). Tremfya, INN-Guselkumab, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"ref_12","unstructured":"EMA (2026, March 15). Skyrizi, INN-Risankizumab, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf."},{"key":"ref_13","unstructured":"EMA (2026, March 15). Cosentyx, INN-Secukinumab, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"ref_14","first-page":"158","article-title":"Immunopathogenic treatment options for psoriasis patients under a restrictive reimbursement environment","volume":"75","author":"Hartmane","year":"2021","journal-title":"Proc. Latv. Acad. Sci. Sect. B Nat. Exact Appl. Sci."},{"key":"ref_15","unstructured":"Nacional Health Service Republic of Latvia (2026, March 15). Diagno\u017eu un Kompens\u0113jamo Z\u0101\u013cu Visp\u0101r\u012bgo Nosaukumu\/Medic\u012bnisko Ier\u012b\u010du Saraksts, Available online: https:\/\/www.vmnvd.gov.lv\/lv\/kompensejamo-zalu-saraksti."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jdv.12688","article-title":"Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry","volume":"29","author":"Medina","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/1346-8138.13853","article-title":"Biologic treatments for elderly patients with psoriasis","volume":"44","author":"Momose","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09546634.2020.1809623","article-title":"Elderly patients with psoriasis: Long-term efficacy and safety of modern treatments","volume":"33","author":"Bakirtzi","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: Guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/1346-8138.17385","article-title":"Real-world safety and efficacy of biologics in elderly patients with psoriasis: A multi-center observational study","volume":"51","author":"Ohata","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.5826\/dpc.1601a5995","article-title":"Biologic Treatment in Elderly Patients with Psoriasis: Focus on Safety and Adherence","volume":"16","year":"2026","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/24755303251327926","article-title":"Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry","volume":"10","author":"Barenbrug","year":"2025","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Arn\u012bte, A., Bondare-Ansberga, V., Reinberga, L., Hartmane, I., and Mika\u017e\u0101ns, I. (2026). Depression, Anxiety and Quality of Life in Patients with Atopic Dermatitis and Psoriasis. Medicina, 62.","DOI":"10.3390\/medicina62010164"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:50:08Z","timestamp":1779699008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050911"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050911","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}